Cited 6 times in
Ramucirumab plus paclitaxel as second-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma: a nationwide real-world outcomes in Korea study (KCSG-ST19-16)
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.